Man is first in U.S. to get newly expanded treatment for advanced prostate cancer (Pluvicto)

madman · Saturday at 4:20 PM

In a quiet clinic in Syracuse, New York, 85-year-old Paul Perry recently became the tip of the spear for a new era in oncological care. A resident of Liverpool and a veteran of a decade-long battle with prostate cancer, Perry made history on July 31st as the first patient in the United States to receive a newly expanded precision treatment. After ten years of managing his condition, the stakes shifted—as Perry noted, "everything was hunky dory until probably the last year." This historic turning point in Syracuse represents more than just a local headline; it is the moment a decades-long struggle met a 21st-century breakthrough, offering a surge of hope for patients facing the most daunting stages of the disease.

2. From Green Light to Injection in 72 Hours

The speed at which this medical milestone moved from federal authorization to the patient’s arm was nothing short of extraordinary. While the FDA formally expanded the approval for the drug Pluvicto on Wednesday, July 31st, the logistical "green light" at the clinical level moved with lightning efficiency over the following weekend. For Perry, the transition from a new regulatory reality to active treatment happened in a mere 72-hour window, reflecting a medical community that is now primed and ready to deploy advanced therapies the moment they are cleared.

"So it was on a Friday that they approved it. The following Monday, I was in the room getting the shot up my arm." — Paul Perry

3. The Precision Revolution: Targeting "That Spot"

The treatment, known as radioligand therapy, represents a sophisticated leap beyond the "blunt force" approach of traditional oncology. Dr. Steven Finkelstein explains that this precision revolution allows doctors to bypass the old risks of broad-spectrum radiation. In the past, patients often worried about collateral damage—radiation hitting the lungs or the heart. Radioligand therapy solves this by tethering a therapeutic agent to an imaging molecule. The medicine essentially "sees" the cancer and delivers the radiation directly to the tumor's coordinates, ensuring the strike hits only "that spot."

"For the first time... We're actually able to both image where the cancer is and then give it a therapeutic agent that is tied to that imaging to be able to treat very, very, very precisely where the cancer is." — Dr. Steven Finkelstein

4. Moving Treatment to the Frontline: The Power of "Earlier"

The significance of the FDA’s July 31st expansion lies in the specific classification of "positive metastatic hormone-sensitive prostate cancer." In the oncology world, "hormone-sensitive" refers to cancer that has begun to spread to other parts of the body but still responds to hormone-suppression therapy. Previously, advanced treatments like Pluvicto were reserved as a "last resort" for patients who had exhausted all other options. By moving this tool to the frontlines, clinicians can adopt a proactive strategy, dismantling the cancer earlier in its progression rather than waiting for it to become resistant and life-threatening.

5. Defying the Odds: Moving Beyond the 3% Survival Ceiling

For years, the prognosis for men whose cancer had migrated to the bones was grim, largely because the primary tool available was chemotherapy. This new milestone is the specific paradigm shift required to dismantle a heartbreaking historical statistic. By moving away from reactive chemotherapy and toward targeted radioligand therapy, the medical community is directly challenging the "survival ceiling" that has limited patient outcomes for decades.

"Prior to its approval, what men had for many years was only chemotherapy. And unfortunately, when you look at the survival of men who had cancer that spread to the bones, only three out of 100 men would be alive five years after diagnosis." — Dr. Steven Finkelstein

6. The "One-Minute" Procedure: 38 Sessions vs. 60 Seconds

The most transformative aspect of this breakthrough is the sheer simplicity of the patient experience. Paul Perry is no stranger to the grueling nature of traditional cancer care; he previously endured 38 taxing sessions of standard radiation. This new protocol effectively replaces that months-long marathon with a sprint. A typical course involves only four to six sessions, and the actual administration of the medicine takes approximately sixty seconds. The juxtaposition is profound: a disease that once required a calendar full of appointments is now being fought with an injection that takes less time than brewing a cup of coffee.

7. A Lifelong Believer in Science

At 85, Paul Perry is a man defined by resilience and a fundamental trust in human ingenuity. Having fought cancer since 2014, he views his place as the first patient in this expanded rollout as a validation of his lifelong philosophy. For Perry, the ability to stand his ground against a metastatic disease is the ultimate proof that scientific persistence pays off.

"I'm a believer in science. A lot of men are not right. I do right because I'm sitting here today at 85 years old, had cancer, you know, back in 2014. And here I sit and I'm, you know, I'm alive. Above the ground, right." — Paul Perry

8. Conclusion: Living Life to the Fullest

The milestone reached in Syracuse marks a decisive victory for precision medicine. By merging high-resolution imaging with targeted therapeutics, the medical field has entered an era where speed and accuracy are no longer mutually exclusive. For patients like Paul Perry, this breakthrough isn’t just about survival statistics—it’s about the quality of the life being saved and the ability to continue living it to the fullest. As we witness the success of this "one-minute" intervention, we must ask: how soon will this level of precision become the standard for every patient facing a metastatic diagnosis?

Dr. Steven Finkelstein

On July 31, 2026, the FDA approved Pluvicto combined with androgen deprivation therapy and an androgen receptor pathway inhibitor, specifically for patients with positive metastatic hormone-sensitive prostate cancer.